Appeal No. 1996-1009
Application No. 07/949,551
Claims 19 through 22, the only other claims pending in this application, have been withdrawn from
appeal (brief, page 1). Claim 15 is representative of the subject matter on appeal and reads as follows:
15. A method for treatment of angina pectoris by administration of a heparin
derivative from bovine or porcine heparin characterised by:
- having a molecular weight equal to or larger than standard
bovine or porcine heparin,
- showing a sulfur content which is equal to or higher than that of said
bovine or porcine heparin,
- having an anticoagulant activity in the anti-FXa assay of less than 10%
of said bovine or porcine heparin it was made from,
showing a ratio of APTT activity over anti-FXa activity of 3-35,
showing a reduced prolongation of bleeding time compared to said
bovine or porcine heparin it was made from as measured in the rat tail
after i.v. administration, and
showing enhancement of the rate of development of coronary
collaterals in dogs equal to or better than clinically used heparin,
in a therapeutic dose to a patient in need of said treatment.
The references relied on by the examiner are:
Naggi et al. (Naggi ‘063) 4,727,063 Feb. 23, 1988
Naggi et al. (Naggi ‘881) 4,948,881 Aug. 14, 1990
Petitou et al. (Petitou) 5,013,724 May 7, 1991
(filed Jul. 11, 1986)
Conti et al. (Conti) 5,164,378 Nov. 17, 1992
(filed Nov. 26, 1990)
- 2 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007